Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “COM701 will be administered via intravenous (IV) infusion once every 3 weeks.”In the company’s words, NCT06888921 on ClinicalTrials.gov
- Tested for
- Ovarian Cancer, Ovarian Cancer Recurrent
- Main trialPhase 1/2
- “The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study…”In the company’s words, NCT06888921 on ClinicalTrials.gov
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab soravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up1
- Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Mar 2027 | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | |
| Phase 1Completed | 30 Jan 2024 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | |
| Phase 1Completed | 1 Apr 2026 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026